GURUFOCUS.COM » STOCK LIST » USA » NAS » NovoCure Ltd (NAS:NVCR) » Definitions » Cash-to-Debt
Switch to:

NovoCure (NAS:NVCR) Cash-to-Debt

: 1.63 (As of Mar. 2023)
View and export this data going back to 2015. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NovoCure's cash to debt ratio for the quarter that ended in Mar. 2023 was 1.63.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NovoCure could pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.

The historical rank and industry rank for NovoCure's Cash-to-Debt or its related term are showing as below:

NVCR' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.45   Med: 1.9   Max: No Debt
Current: 1.63

During the past 10 years, NovoCure's highest Cash to Debt Ratio was No Debt. The lowest was 1.45. And the median was 1.90.

NVCR's Cash-to-Debt is ranked worse than
57.56% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: 2.52 vs NVCR: 1.63

NovoCure Cash-to-Debt Historical Data

The historical data trend for NovoCure's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.99 1.90 1.63 1.66

NovoCure Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.61 1.64 1.67 1.66 1.63

Competitive Comparison

For the Medical Devices subindustry, NovoCure's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

NovoCure Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NovoCure's Cash-to-Debt falls in comparison to its industry or sector. The grey bar indicates the Cash-to-Debt's extreme value range as defined by GuruFocus.



NovoCure Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NovoCure's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

NovoCure's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovoCure  (NAS:NVCR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


NovoCure Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NovoCure's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (NAS:NVCR) Business Description

NovoCure logo
Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
Executives
Arye Barak Ben officer: General Counsel TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
William Patrick Burke officer: Chief Human Resources Officer 195 COMMERCE WAY, PORTSMOUTH NH 03801
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Ashley Cordova officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Frank X Leonard officer: Chief Development Officer 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Uri Weinberg officer: Chief Science Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Ely Benaim officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Pritesh Shah officer: Chief Commercial Officer C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Sherilyn S Mccoy director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David Hung director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Martin J. Madden director C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Steve Futrell 10 percent owner 780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Frances Janis 10 percent owner 780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017
Michael D Granoff 10 percent owner 780 THIRD AVENUE, 46TH FLOOR, NEW YORK NY 10017

NovoCure (NAS:NVCR) Headlines